Skip to main content

Advertisement

SpringerLink
Log in

Erythropoietin: physiology and molecular mechanisms

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Erythropoietin, the primary regulator of erythropoiesis, is produced by the kidney and levels vary inversely with oxygen availability. Hypoxia-inducible factor-1 (HIF-1), a major transcriptional regulator of several hypoxia-sensitive genes, including erythropoietin, is functionally deactivated by oxygen in a reaction catalyzed by prolyl hydroxylase. Erythropoietin acts by binding to a specific trans-membrane dimeric receptor which has been found in erythroid and non-erythroid cell types. The interaction between erythropoietin and its receptor ultimately leads to conformational change and phosphorylation of the receptor and expression of genes coding for proteins that are anti-apoptotic. Development of erythropoietin stimulating agents is an area of active research. To date, research has focused on activating the erythropoietin receptor, prevention of HIF-1 inactivation, and gene therapy. Even with biologically effective therapies, defining appropriate hemoglobin targets remains challenging. For example, despite decades of clinical trials, target hemoglobin levels in chronic kidney disease remain uncertain, as hemoglobin targets above 13 g/dl have been associated with both benefit (quality of life) and harm (cardiovascular events).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Carnot P (1906) Sur l’activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris) 143:384–386

    CAS  Google Scholar 

  2. Reissmann KR (1959) Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. Blood 5:347–380

    Google Scholar 

  3. Jacobson LO (1957) Role of the kidney in erythropoiesis. Nature 179:633

    Article  PubMed  CAS  Google Scholar 

  4. Miyake T (1977) Purification of human erythropoietin. J Biol Chem 252:5558–5564

    PubMed  CAS  Google Scholar 

  5. Lin FK et al (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 92:7580–7584

    Article  Google Scholar 

  6. Jacobs K (1985) Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 313:806–810

    Article  PubMed  CAS  Google Scholar 

  7. Fisher JW (1997) Erythropoietin: physiologic and pharmacologic aspects. Proc Soc Exp Biol 16:358–369

    Google Scholar 

  8. Adamson JW (1988) Erythropoietin: in vitro and in vivo studies of the regulation of erythropoiesis. Schweiz Med Wochenschr 118:1501–1506

    PubMed  CAS  Google Scholar 

  9. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449–489

    PubMed  CAS  Google Scholar 

  10. Manolis AS (2005) Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 5:355–375

    Article  PubMed  CAS  Google Scholar 

  11. Wang GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304–4308

    Article  PubMed  CAS  Google Scholar 

  12. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1–3

    Article  PubMed  CAS  Google Scholar 

  13. Zhu H (2001) Signal transduction: how do cells sense oxygen? Science 292:449–451

    Article  PubMed  CAS  Google Scholar 

  14. Prchal JT (2003) Delivery on demand a new era of gene therapy? N Engl J Med 348:1282–1283

    Article  PubMed  Google Scholar 

  15. Ang SO (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32:614–621

    Article  PubMed  CAS  Google Scholar 

  16. Rossert J (2005) Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 20:1025–1028

    Article  PubMed  CAS  Google Scholar 

  17. Lacombe C (1999) The molecular biology of erythropoietin. Nephrol Dial Transplant 14 Suppl 2:22–28

    Article  PubMed  CAS  Google Scholar 

  18. Ratajczak J (2001) Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 115:195–204

    Article  PubMed  CAS  Google Scholar 

  19. Digicaylioglu M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92:3717–3720

    Article  PubMed  CAS  Google Scholar 

  20. Juul SE (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235–249

    Article  PubMed  CAS  Google Scholar 

  21. Anagnostou A et al (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91:3974–3978

    Article  PubMed  CAS  Google Scholar 

  22. Silva M (1999) Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274:22165–22169

    Article  PubMed  CAS  Google Scholar 

  23. Kashii Y (2000) A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96:941–949

    PubMed  CAS  Google Scholar 

  24. Digicaylioglu M (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641–647

    Article  PubMed  CAS  Google Scholar 

  25. Yang CW (2003) Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17:1754–1755

    Article  PubMed  CAS  Google Scholar 

  26. Wu H (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59–67

    Article  PubMed  CAS  Google Scholar 

  27. Lin CS (1996) Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 10:154–164

    Article  PubMed  CAS  Google Scholar 

  28. Vaziri ND (2001) Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10:633–637

    Article  PubMed  CAS  Google Scholar 

  29. Vaziri ND (1996) Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113–E122

    PubMed  CAS  Google Scholar 

  30. Vaziri ND et al (1995) In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269:F838–F845

    PubMed  CAS  Google Scholar 

  31. Marrero MB (1998) Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53:1259–1268

    Article  PubMed  CAS  Google Scholar 

  32. Miller BA (1994) Mechanisms of erythropoietin signal transduction: involvement of calcium channels. Proc Soc Exp Biol Med 206:263–267

    PubMed  CAS  Google Scholar 

  33. Lebel M (1998) Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 20:939–951

    PubMed  CAS  Google Scholar 

  34. Rodrigue ME (2003) Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol 41:388–395

    Article  PubMed  CAS  Google Scholar 

  35. Eggena P (1991) Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261:E642–E646

    PubMed  CAS  Google Scholar 

  36. Barrett JD (1998) Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 6:1749–1757

    Article  Google Scholar 

  37. Lebel M (2006) Antihypertensive and renal protective effects of Renin-Angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 19:1286–1292

    Article  PubMed  CAS  Google Scholar 

  38. Casadevall N (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475

    Article  PubMed  CAS  Google Scholar 

  39. Bennett CL (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403–1408

    Article  PubMed  CAS  Google Scholar 

  40. Boven K (2005) Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 20 Suppl 3:iii33–40

    Article  PubMed  CAS  Google Scholar 

  41. Boven K (2006) The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67:2346–2353

    Article  Google Scholar 

  42. Macdougall IC (2006) Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368(9539):947–953

    Article  PubMed  CAS  Google Scholar 

  43. Egrie JC (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 Suppl 1:3–10

    Article  PubMed  CAS  Google Scholar 

  44. Macdougall IC (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392–2395

    PubMed  CAS  Google Scholar 

  45. Nissenson AR (2002) Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110–118

    Article  PubMed  CAS  Google Scholar 

  46. Vanrenterghem Y (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167–2175

    Article  PubMed  CAS  Google Scholar 

  47. Jadoul M (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898–903

    Article  PubMed  CAS  Google Scholar 

  48. Macdougall IC (2006) CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436–440

    Google Scholar 

  49. de Francisco AL (2006) Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 60:1687–1696

    Article  PubMed  CAS  Google Scholar 

  50. Kochendoerfer GG (2003) Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299(5608):884–887

    Article  PubMed  CAS  Google Scholar 

  51. Sytkowski AJ (1999) An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773–24778

    Article  PubMed  CAS  Google Scholar 

  52. Wrighton NC (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274):458–464

    Article  PubMed  CAS  Google Scholar 

  53. Stead RB (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830–1834

    Article  PubMed  CAS  Google Scholar 

  54. Qureshi SA (1999) Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96:12156–12161

    Article  PubMed  CAS  Google Scholar 

  55. Schofield CJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343–354

    Article  PubMed  CAS  Google Scholar 

  56. Safran M (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 103:105–110

    Article  PubMed  CAS  Google Scholar 

  57. Schwenter F (2004) Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 15:669–680

    Article  PubMed  CAS  Google Scholar 

  58. Fattori E (2005) Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 7:228–236

    Article  PubMed  CAS  Google Scholar 

  59. Rivera VM (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105:1424–1430

    Article  PubMed  CAS  Google Scholar 

  60. Lippin Y (2005) Human erythropoietin gene therapy for patients with chronic renal failure. Blood 106:2280–2286

    Article  PubMed  CAS  Google Scholar 

  61. Binley K (2002) Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 100:2406–2413

    Article  PubMed  CAS  Google Scholar 

  62. Eschbach JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73–78

    Article  PubMed  CAS  Google Scholar 

  63. Eschbach JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158–163

    Article  PubMed  CAS  Google Scholar 

  64. Foley RN, Ritz E (2005) Cardiovascular risk factors. In: Davsion AM et al (eds) Oxford textbook of clinical nephrology. Oxford, United Kingdom

    Google Scholar 

  65. Besarab A (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590

    Article  PubMed  CAS  Google Scholar 

  66. Furuland H (2003) A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353–361

    Article  PubMed  CAS  Google Scholar 

  67. Foley RN (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325–1335

    Article  PubMed  CAS  Google Scholar 

  68. Parfrey PS (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180–2189

    Article  PubMed  Google Scholar 

  69. Levin A (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46:799–811

    Article  PubMed  CAS  Google Scholar 

  70. Suzuki M (1989) Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 76:179–192

    PubMed  CAS  Google Scholar 

  71. Roger SD (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15:148–156

    Article  PubMed  CAS  Google Scholar 

  72. Nissenson AR (1995) Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5:1517–1529

    PubMed  CAS  Google Scholar 

  73. Bahlmann J (1991) Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 88:90–106

    PubMed  CAS  Google Scholar 

  74. Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300:573–578

    Article  Google Scholar 

  75. Roth D (1994) Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777–784

    PubMed  CAS  Google Scholar 

  76. Revicki DA (1995) Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548–554

    Article  PubMed  CAS  Google Scholar 

  77. Kuriyama S (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176–185

    PubMed  CAS  Google Scholar 

  78. Sikole A (1993) Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17:977–984

    PubMed  CAS  Google Scholar 

  79. Weiss LG (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15:2014–2019

    Article  PubMed  CAS  Google Scholar 

  80. Lim VS (1989) Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108–114

    PubMed  CAS  Google Scholar 

  81. Kleinman KS (1989) The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 14:486–495

    PubMed  CAS  Google Scholar 

  82. McMahon LP (1999) Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182–1187

    Article  PubMed  CAS  Google Scholar 

  83. McMahon LP (1992) Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7:1199–1206

    PubMed  CAS  Google Scholar 

  84. Watson AJ (1990) Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 89:432–435

    Article  PubMed  CAS  Google Scholar 

  85. Morris KP (1993) Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. Arch Dis Child 68:644–648

    PubMed  CAS  Google Scholar 

  86. Drueke TB (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084

    Article  PubMed  CAS  Google Scholar 

  87. Singh AK (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098

    Article  PubMed  CAS  Google Scholar 

  88. Rossert J (2006) Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47:738–750

    Article  PubMed  CAS  Google Scholar 

  89. Macdougall IC (2007) Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 22:784–793

    Article  PubMed  CAS  Google Scholar 

  90. Phrommintikul A (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369(9559):381–388

    Article  PubMed  CAS  Google Scholar 

  91. Foley RN et al (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53–61

    Article  PubMed  CAS  Google Scholar 

  92. Ma JZ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610–619

    PubMed  CAS  Google Scholar 

  93. Hansson L (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118):1755–1762

    Article  PubMed  CAS  Google Scholar 

  94. Locatelli F (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 Suppl 2:ii1–47

    Article  PubMed  Google Scholar 

  95. KDOQI (2006) National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47(5 Suppl 3):S11–145

    Google Scholar 

  96. KDOQI (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471–530

    Article  Google Scholar 

  97. http://www.fda.gov/cder/drug/infopage/RHE

Download references

Author information

Authors and Affiliations

  1. Chronic Disease Research Group, 914 South 8th Street, Suite D-253, Minneapolis, MN, 55404, USA

    Robert N. Foley

Authors
  1. Robert N. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert N. Foley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foley, R.N. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 13, 405–414 (2008). https://doi.org/10.1007/s10741-008-9083-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-008-9083-0

Keywords

Search

Navigation